Which has preferable earnings and valuation, ONC or QGEN?

Qiagen has lower revenue, but higher earnings than BeOne Medicines. Qiagen is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BeOne Medicines $5.34B 6.44 $286.93M $4.47 70.11 Qiagen $2.09B 4.07 $424.88M $1.91 21.59

Is ONC or QGEN more profitable?

Qiagen has a net margin of 19.16% compared to BeOne Medicines' net margin of 8.94%. Qiagen's return on equity of 14.40% beat BeOne Medicines' return on equity. Company Net Margins Return on Equity Return on Assets BeOne Medicines 8.94% 12.06% 6.69% Qiagen 19.16% 14.40% 8.40%

Does the media favor ONC or QGEN?

In the previous week, BeOne Medicines had 6 more articles in the media than Qiagen. MarketBeat recorded 16 mentions for BeOne Medicines and 10 mentions for Qiagen. Qiagen's average media sentiment score of 0.86 beat BeOne Medicines' score of 0.57 indicating that Qiagen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BeOne Medicines 7 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Qiagen 6 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, QGEN or MRNA?

Qiagen has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Qiagen $2.09B 4.07 $424.88M $1.91 21.59 Moderna $1.94B 12.77 -$2.82B -$8.15 N/A

Is QGEN or MRNA more profitable?

Qiagen has a net margin of 19.16% compared to Moderna's net margin of -143.55%. Qiagen's return on equity of 14.40% beat Moderna's return on equity. Company Net Margins Return on Equity Return on Assets Qiagen 19.16% 14.40% 8.40% Moderna -143.55% -26.64% -19.32%

Does the media refer more to QGEN or MRNA?

In the previous week, Moderna had 5 more articles in the media than Qiagen. MarketBeat recorded 15 mentions for Moderna and 10 mentions for Qiagen. Qiagen's average media sentiment score of 0.86 beat Moderna's score of 0.58 indicating that Qiagen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Qiagen 6 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Moderna 3 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, QGEN or ROIV?

Qiagen has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Qiagen $2.09B 4.07 $424.88M $1.91 21.59 Roivant Sciences $8.26M 3,017.63 -$299.77M -$0.60 N/A

Is QGEN or ROIV more profitable?

Qiagen has a net margin of 19.16% compared to Roivant Sciences' net margin of -3,629.19%. Qiagen's return on equity of 14.40% beat Roivant Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Qiagen 19.16% 14.40% 8.40% Roivant Sciences -3,629.19% -20.54% -19.43%

Does the media prefer QGEN or ROIV?

In the previous week, Qiagen had 4 more articles in the media than Roivant Sciences. MarketBeat recorded 10 mentions for Qiagen and 6 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 1.38 beat Qiagen's score of 0.86 indicating that Roivant Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Qiagen 6 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Roivant Sciences 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, INSM or QGEN?

Qiagen has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Insmed $606.42M 38.94 -$1.28B -$5.75 N/A Qiagen $2.09B 4.07 $424.88M $1.91 21.59

Is INSM or QGEN more profitable?

Qiagen has a net margin of 19.16% compared to Insmed's net margin of -144.44%. Qiagen's return on equity of 14.40% beat Insmed's return on equity. Company Net Margins Return on Equity Return on Assets Insmed -144.44% -130.11% -51.57% Qiagen 19.16% 14.40% 8.40%

Does the media favor INSM or QGEN?

In the previous week, Insmed had 7 more articles in the media than Qiagen. MarketBeat recorded 17 mentions for Insmed and 10 mentions for Qiagen. Insmed's average media sentiment score of 0.92 beat Qiagen's score of 0.86 indicating that Insmed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insmed 9 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Qiagen 6 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, QGEN or BNTX?

Qiagen has higher earnings, but lower revenue than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Qiagen $2.09B 4.07 $424.88M $1.91 21.59 BioNTech $3.25B 7.14 -$1.29B -$5.88 N/A

Is QGEN or BNTX more profitable?

Qiagen has a net margin of 19.16% compared to BioNTech's net margin of -44.39%. Qiagen's return on equity of 14.40% beat BioNTech's return on equity. Company Net Margins Return on Equity Return on Assets Qiagen 19.16% 14.40% 8.40% BioNTech -44.39% -5.30% -4.62%

Does the media refer more to QGEN or BNTX?

In the previous week, Qiagen had 4 more articles in the media than BioNTech. MarketBeat recorded 10 mentions for Qiagen and 6 mentions for BioNTech. BioNTech's average media sentiment score of 1.03 beat Qiagen's score of 0.86 indicating that BioNTech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Qiagen 6 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioNTech 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Qiagen (QGEN) Competitors

$41.23 -0.28 (-0.67%)

As of 10:56 AM Eastern

Compare

QGEN vs. ONC, MRNA, ROIV, INSM, and BNTX

Should you buy Qiagen stock or one of its competitors? MarketBeat compares Qiagen with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Qiagen include BeOne Medicines (ONC), Moderna (MRNA), Roivant Sciences (ROIV), Insmed (INSM), and BioNTech (BNTX). These companies are all part of the "pharmaceutical products" industry.

How does Qiagen compare to BeOne Medicines?

BeOne Medicines (NASDAQ:ONC) and Qiagen (NYSE:QGEN) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, analyst recommendations, institutional ownership, dividends, profitability, earnings and risk.

48.6% of BeOne Medicines shares are held by institutional investors. Comparatively, 70.0% of Qiagen shares are held by institutional investors. 6.2% of BeOne Medicines shares are held by company insiders. Comparatively, 9.0% of Qiagen shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Qiagen has lower revenue, but higher earnings than BeOne Medicines. Qiagen is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeOne Medicines	$5.34B	6.44	$286.93M	$4.47	70.11
Qiagen	$2.09B	4.07	$424.88M	$1.91	21.59

BeOne Medicines presently has a consensus target price of $390.92, indicating a potential upside of 24.74%. Qiagen has a consensus target price of $43.34, indicating a potential upside of 5.12%. Given BeOne Medicines' stronger consensus rating and higher possible upside, equities research analysts clearly believe BeOne Medicines is more favorable than Qiagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeOne Medicines	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.80
Qiagen	1 Sell rating(s)	8 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.36

In the previous week, BeOne Medicines had 6 more articles in the media than Qiagen. MarketBeat recorded 16 mentions for BeOne Medicines and 10 mentions for Qiagen. Qiagen's average media sentiment score of 0.86 beat BeOne Medicines' score of 0.57 indicating that Qiagen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BeOne Medicines	7 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Qiagen	6 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BeOne Medicines has a beta of 0.49, suggesting that its stock price is 51% less volatile than the broader market. Comparatively, Qiagen has a beta of 0.64, suggesting that its stock price is 36% less volatile than the broader market.

Qiagen has a net margin of 19.16% compared to BeOne Medicines' net margin of 8.94%. Qiagen's return on equity of 14.40% beat BeOne Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BeOne Medicines	8.94%	12.06%	6.69%
Qiagen	19.16%	14.40%	8.40%

Summary

BeOne Medicines and Qiagen tied by winning 8 of the 16 factors compared between the two stocks.

How does Qiagen compare to Moderna?

Qiagen (NYSE:QGEN) and Moderna (NASDAQ:MRNA) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, media sentiment, profitability, dividends, risk and institutional ownership.

In the previous week, Moderna had 5 more articles in the media than Qiagen. MarketBeat recorded 15 mentions for Moderna and 10 mentions for Qiagen. Qiagen's average media sentiment score of 0.86 beat Moderna's score of 0.58 indicating that Qiagen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Qiagen	6 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Moderna	3 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Qiagen has a net margin of 19.16% compared to Moderna's net margin of -143.55%. Qiagen's return on equity of 14.40% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Qiagen	19.16%	14.40%	8.40%
Moderna	-143.55%	-26.64%	-19.32%

Qiagen currently has a consensus target price of $43.34, suggesting a potential upside of 5.12%. Moderna has a consensus target price of $38.27, suggesting a potential downside of 38.82%. Given Qiagen's stronger consensus rating and higher probable upside, equities research analysts clearly believe Qiagen is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qiagen	1 Sell rating(s)	8 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.36
Moderna	5 Sell rating(s)	10 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.82

Qiagen has a beta of 0.64, suggesting that its share price is 36% less volatile than the broader market. Comparatively, Moderna has a beta of 0.94, suggesting that its share price is 6% less volatile than the broader market.

70.0% of Qiagen shares are held by institutional investors. Comparatively, 75.3% of Moderna shares are held by institutional investors. 9.0% of Qiagen shares are held by insiders. Comparatively, 10.8% of Moderna shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Qiagen has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qiagen	$2.09B	4.07	$424.88M	$1.91	21.59
Moderna	$1.94B	12.77	-$2.82B	-$8.15	N/A

Summary

Qiagen beats Moderna on 12 of the 17 factors compared between the two stocks.

How does Qiagen compare to Roivant Sciences?

Qiagen (NYSE:QGEN) and Roivant Sciences (NASDAQ:ROIV) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, media sentiment, valuation, institutional ownership, earnings and dividends.

Qiagen has a beta of 0.64, indicating that its share price is 36% less volatile than the broader market. Comparatively, Roivant Sciences has a beta of 1.11, indicating that its share price is 11% more volatile than the broader market.

Qiagen has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qiagen	$2.09B	4.07	$424.88M	$1.91	21.59
Roivant Sciences	$8.26M	3,017.63	-$299.77M	-$0.60	N/A

70.0% of Qiagen shares are owned by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are owned by institutional investors. 9.0% of Qiagen shares are owned by insiders. Comparatively, 10.8% of Roivant Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Qiagen has a net margin of 19.16% compared to Roivant Sciences' net margin of -3,629.19%. Qiagen's return on equity of 14.40% beat Roivant Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Qiagen	19.16%	14.40%	8.40%
Roivant Sciences	-3,629.19%	-20.54%	-19.43%

Qiagen currently has a consensus price target of $43.34, suggesting a potential upside of 5.12%. Roivant Sciences has a consensus price target of $33.59, suggesting a potential downside of 3.07%. Given Qiagen's higher possible upside, research analysts clearly believe Qiagen is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qiagen	1 Sell rating(s)	8 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.36
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, Qiagen had 4 more articles in the media than Roivant Sciences. MarketBeat recorded 10 mentions for Qiagen and 6 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 1.38 beat Qiagen's score of 0.86 indicating that Roivant Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Qiagen	6 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Roivant Sciences	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Qiagen beats Roivant Sciences on 11 of the 17 factors compared between the two stocks.

How does Qiagen compare to Insmed?

Insmed (NASDAQ:INSM) and Qiagen (NYSE:QGEN) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, dividends, institutional ownership, media sentiment, risk, profitability, analyst recommendations and valuation.

Insmed currently has a consensus price target of $211.05, indicating a potential upside of 93.72%. Qiagen has a consensus price target of $43.34, indicating a potential upside of 5.12%. Given Insmed's stronger consensus rating and higher possible upside, research analysts clearly believe Insmed is more favorable than Qiagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.96
Qiagen	1 Sell rating(s)	8 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.36

In the previous week, Insmed had 7 more articles in the media than Qiagen. MarketBeat recorded 17 mentions for Insmed and 10 mentions for Qiagen. Insmed's average media sentiment score of 0.92 beat Qiagen's score of 0.86 indicating that Insmed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insmed	9 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Qiagen	6 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Insmed has a beta of 0.78, suggesting that its share price is 22% less volatile than the broader market. Comparatively, Qiagen has a beta of 0.64, suggesting that its share price is 36% less volatile than the broader market.

Qiagen has a net margin of 19.16% compared to Insmed's net margin of -144.44%. Qiagen's return on equity of 14.40% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insmed	-144.44%	-130.11%	-51.57%
Qiagen	19.16%	14.40%	8.40%

70.0% of Qiagen shares are owned by institutional investors. 2.1% of Insmed shares are owned by company insiders. Comparatively, 9.0% of Qiagen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Qiagen has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insmed	$606.42M	38.94	-$1.28B	-$5.75	N/A
Qiagen	$2.09B	4.07	$424.88M	$1.91	21.59

Summary

Qiagen beats Insmed on 9 of the 16 factors compared between the two stocks.

How does Qiagen compare to BioNTech?

Qiagen (NYSE:QGEN) and BioNTech (NASDAQ:BNTX) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, earnings, risk, profitability and media sentiment.

In the previous week, Qiagen had 4 more articles in the media than BioNTech. MarketBeat recorded 10 mentions for Qiagen and 6 mentions for BioNTech. BioNTech's average media sentiment score of 1.03 beat Qiagen's score of 0.86 indicating that BioNTech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Qiagen	6 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioNTech	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Qiagen has a beta of 0.64, indicating that its share price is 36% less volatile than the broader market. Comparatively, BioNTech has a beta of 1.32, indicating that its share price is 32% more volatile than the broader market.

Qiagen currently has a consensus target price of $43.34, indicating a potential upside of 5.12%. BioNTech has a consensus target price of $129.13, indicating a potential upside of 40.89%. Given BioNTech's stronger consensus rating and higher possible upside, analysts plainly believe BioNTech is more favorable than Qiagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qiagen	1 Sell rating(s)	8 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.36
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74

Qiagen has higher earnings, but lower revenue than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qiagen	$2.09B	4.07	$424.88M	$1.91	21.59
BioNTech	$3.25B	7.14	-$1.29B	-$5.88	N/A

70.0% of Qiagen shares are owned by institutional investors. Comparatively, 15.5% of BioNTech shares are owned by institutional investors. 9.0% of Qiagen shares are owned by insiders. Comparatively, 19.2% of BioNTech shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Qiagen has a net margin of 19.16% compared to BioNTech's net margin of -44.39%. Qiagen's return on equity of 14.40% beat BioNTech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Qiagen	19.16%	14.40%	8.40%
BioNTech	-44.39%	-5.30%	-4.62%

Summary

Qiagen and BioNTech tied by winning 8 of the 16 factors compared between the two stocks.

Get Qiagen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding QGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

QGEN vs. The Competition

Export

Metric	Qiagen	MED Industry	Medical Sector	NYSE Exchange
Market Cap	$8.50B	$3.72B	$6.91B	$23.47B
Dividend Yield	0.85%	2.20%	2.68%	4.19%
P/E Ratio	21.55	21.46	27.23	30.96
Price / Sales	4.07	301.02	573.53	19.76
Price / Cash	12.11	146.26	49.25	33.10
Price / Book	2.30	8.40	10.85	4.78
Net Income	$424.88M	$23.83M	$3.59B	$1.07B
7 Day Performance	-0.70%	-4.01%	-2.26%	0.50%
1 Month Performance	12.48%	2.73%	1.89%	2.18%
1 Year Performance	-18.86%	43.29%	23.86%	16.82%

Qiagen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
QGEN Qiagen	4.0076 of 5 stars	$41.23 -0.7%	$43.34 +5.1%	-18.4%	$8.50B	$2.09B	21.55	5,654	Positive News Analyst Forecast Gap Down
ONC BeOne Medicines	4.7199 of 5 stars	$303.96 +1.8%	$391.38 +28.8%	+13.7%	$32.77B	$5.34B	68.00	12,000	Analyst Forecast Insider Trade
MRNA Moderna	1.8008 of 5 stars	$67.01 -1.8%	$38.27 -42.9%	+97.0%	$27.09B	$1.94B	N/A	4,700	Gap Down
ROIV Roivant Sciences	1.8652 of 5 stars	$34.51 -4.1%	$33.59 -2.7%	+194.0%	$25.87B	$8.26M	N/A	860
INSM Insmed	4.1298 of 5 stars	$109.14 -5.6%	$211.00 +93.3%	+2.7%	$25.06B	$606.42M	N/A	1,664	News Coverage Analyst Forecast Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:QGEN) was last updated on 7/17/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Qiagen (QGEN) Competitors

QGEN vs. ONC, MRNA, ROIV, INSM, and BNTX

How does Qiagen compare to BeOne Medicines?

Summary

How does Qiagen compare to Moderna?

Summary

How does Qiagen compare to Roivant Sciences?

Summary

How does Qiagen compare to Insmed?

Summary

How does Qiagen compare to BioNTech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QGEN vs. The Competition

Qiagen Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Qiagen (QGEN) Competitors

QGEN vs. ONC, MRNA, ROIV, INSM, and BNTX

How does Qiagen compare to BeOne Medicines?

Do institutionals & insiders believe in ONC or QGEN?

Which has preferable earnings and valuation, ONC or QGEN?

Do analysts recommend ONC or QGEN?

Does the media favor ONC or QGEN?

Which has more risk and volatility, ONC or QGEN?

Is ONC or QGEN more profitable?

Summary

How does Qiagen compare to Moderna?

Does the media refer more to QGEN or MRNA?

Is QGEN or MRNA more profitable?

Do analysts rate QGEN or MRNA?

Which has more risk & volatility, QGEN or MRNA?

Do insiders & institutionals hold more shares of QGEN or MRNA?

Which has preferable valuation and earnings, QGEN or MRNA?

Summary

How does Qiagen compare to Roivant Sciences?

Which has more volatility and risk, QGEN or ROIV?

Which has better earnings and valuation, QGEN or ROIV?

Do institutionals and insiders hold more shares of QGEN or ROIV?

Is QGEN or ROIV more profitable?

Do analysts prefer QGEN or ROIV?

Does the media prefer QGEN or ROIV?

Summary

How does Qiagen compare to Insmed?

Do analysts prefer INSM or QGEN?

Does the media favor INSM or QGEN?

Which has more risk and volatility, INSM or QGEN?

Is INSM or QGEN more profitable?

Do insiders & institutionals have more ownership in INSM or QGEN?

Which has higher valuation & earnings, INSM or QGEN?

Summary

How does Qiagen compare to BioNTech?

Does the media refer more to QGEN or BNTX?

Which has more risk & volatility, QGEN or BNTX?

Do analysts prefer QGEN or BNTX?

Which has stronger earnings and valuation, QGEN or BNTX?

Do insiders and institutionals have more ownership in QGEN or BNTX?

Is QGEN or BNTX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QGEN vs. The Competition

Qiagen Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools